Is Anthem Bioscienc overvalued or undervalued?

As of 29 August 2025, the valuation grade for Anthem Bioscienc has moved from does not qualify to very expensive. This indicates that the company is currently overvalued. Key ratios supporting this assessment include a PE Ratio of 90.82, an EV to EBITDA of 65.82, and a Price to Book Value of 18.59, all of which are significantly higher than industry norms.
In comparison with peers, Anthem Bioscienc's PE Ratio is substantially higher than Sun Pharma's 33.34 and Divi's Lab's 70.28, both of which are classified as expensive or very expensive, respectively. The PEG Ratio for Anthem is notably at 0.00, which suggests a lack of growth relative to its price, further reinforcing the overvaluation narrative. Additionally, while Anthem has shown a 4.51% return over the past month, it has underperformed against the Sensex, which declined by 1.88% in the same period.